Cargando…

Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis

OBJECTIVES: To identify the therapeutic range for etanercept and to assess the incidence of anti-etanercept antibody formation. METHODS: Associations between etanercept serum concentration and disease activity as well as treatment response were examined in a longitudinal observational study of rheum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gehin, Johanna Elin, Syversen, Silje Watterdal, Warren, David John, Goll, Guro Løvik, Sexton, Joseph, Bolstad, Nils, Hammer, Hilde Berner
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Treatments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8679136/ https://www.ncbi.nlm.nih.gov/pubmed/34911811 http://dx.doi.org/10.1136/rmdopen-2021-001985

Ejemplares similares

Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
por: Gehin, Johanna Elin, et al.
Publicado: (2022)

Associations between certolizumab pegol serum levels, anti-drug antibodies and treatment response in patients with inflammatory joint diseases: data from the NOR-DMARD study
por: Gehin, Johanna Elin, et al.
Publicado: (2019)

Risk factors for anti‐drug antibody formation to infliximab: Secondary analyses of a randomised controlled trial
por: Brun, Marthe Kirkesæther, et al.
Publicado: (2022)

Rheumatoid factor and falsely elevated results in commercial immunoassays: data from an early arthritis cohort
por: Gehin, Johanna E., et al.
Publicado: (2021)

Therapeutic drug monitoring of infliximab compared to standard clinical treatment with infliximab: study protocol for a randomised, controlled, open, parallel-group, phase IV study (the NOR-DRUM study)
por: Syversen, Silje W, et al.
Publicado: (2020)

Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
por: Krieckaert, Charlotte, et al.
Publicado: (2022)

Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis
por: Lindström, Ulf, et al.
Publicado: (2019)

A high serum level of eotaxin (CCL 11) is associated with less radiographic progression in early rheumatoid arthritis patients
por: Syversen, Silje W, et al.
Publicado: (2008)

Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
por: Syversen, Silje Watterdal, et al.
Publicado: (2022)

Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
por: Bjørlykke, Kristin H, et al.
Publicado: (2023)

Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis
por: Glintborg, Bente, et al.
Publicado: (2019)

Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
por: Jyssum, Ingrid, et al.
Publicado: (2022)

Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Is synovial hypertrophy without Doppler activity sensitive to change? Post-hoc analysis from a rheumatoid arthritis ultrasound study
por: Terslev, Lene, et al.
Publicado: (2018)

Gastrointestinal perforations in patients with rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs in Sweden: a nationwide cohort study
por: Barbulescu, Andrei, et al.
Publicado: (2020)

Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis
por: Hammer, Hilde Berner, et al.
Publicado: (2020)

The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
por: Christensen, Ingrid Egeland, et al.
Publicado: (2022)

Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy
por: Provan, Sella Aarrestad, et al.
Publicado: (2020)

Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting
por: Liang, Huifang, et al.
Publicado: (2019)

Long-term safety of certolizumab pegol in rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis and Crohn’s disease: a pooled analysis of 11 317 patients across clinical trials
por: Curtis, Jeffrey R, et al.
Publicado: (2019)

Missing data in randomised controlled trials of rheumatoid arthritis drug therapy are substantial and handled inappropriately
por: Khan, Nasim A, et al.
Publicado: (2021)

Is methotrexate safe for men with an immune-mediated inflammatory disease and an active desire to become a father? Results of a prospective cohort study (iFAME-MTX)
por: Perez-Garcia, Luis Fernando, et al.
Publicado: (2023)

Regulation of peripheral classical and non-classical monocytes on infliximab treatment in patients with rheumatoid arthritis and ankylosing spondylitis
por: Aeberli, Daniel, et al.
Publicado: (2016)

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure
por: Rossignol, Patrick, et al.
Publicado: (2020)

Incidence of facial nerve palsies stratified by DMARD treatment in patients with rheumatoid arthritis: data from the RABBIT register
por: Meissner, Yvette, et al.
Publicado: (2020)

Efficacy and safety of emapalumab in macrophage activation syndrome
por: De Benedetti, Fabrizio, et al.
Publicado: (2023)

Treating neglected tropical diseases
por: Hopkins, Adrian
Publicado: (2013)

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
por: Mease, Philip, et al.
Publicado: (2020)

Pilot study of tocilizumab monotherapy for active chronic periaortitis
por: Wang, Anqi, et al.
Publicado: (2023)

Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure
por: Burmester, Gerd R, et al.
Publicado: (2021)

Pneumococcal vaccination in autoimmune rheumatic diseases
por: Rákóczi, Éva, et al.
Publicado: (2017)

JAK inhibitors disrupt T cell-induced proinflammatory macrophage activation
por: Nyirenda, Mukanthu H, et al.
Publicado: (2023)

Influence of aromatase inhibitors therapy on the occurrence of rheumatoid arthritis in women with breast cancer: results from a large population-based study of the Italian Society for Rheumatology
por: Caprioli, Marta, et al.
Publicado: (2017)

Evaluation of response to 13-valent conjugated pneumococcal vaccination in patients with rheumatoid arthritis receiving upadacitinib: results from a phase 2 open-label extension study
por: Winthrop, Kevin, et al.
Publicado: (2022)

Antirheumatic drugs for cardiovascular disease prevention: the case for colchicine
por: Lems, Willem, et al.
Publicado: (2021)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Etanercept in the treatment of rheumatoid arthritis
por: Haraoui, Boulos, et al.
Publicado: (2007)

Etanercept for Treating Rheumatoid Arthritis
por: Moreland, Larry W
Publicado: (2000)

JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications
por: Russell, Mark D, et al.
Publicado: (2023)

Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews
por: Rodriguez-García, Sebastián Cruz, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_38scnsd6h01oinu57i1k3he7nt